XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

Introduction. On 4 and 5 November 2022, Madrid hosted the 15th edition of the Post-ECTRIMS Meeting, where neurologists specialised in multiple sclerosis outlined the latest developments presented at the 2022 ECTRIMS Congress, held in Amsterdam from 26 to 28 October. Aim. To synthesise the content pr...

Descripción completa

Detalles Bibliográficos
Autores: Fernández, Óscar, Montalban, Xavier, Agüera, Eduardo, Aladro, Yolanda, Alonso, Ana, Arroyo, Rafael, Brieva, Luis, Calles, Carmen, Costa Frossard, Lucienne, Eichau, S., García Domínguez, José M., Hernández, M. A., Landete, Lamberto, Llaneza, Miguel, Llufriu, Sara, Meca Lallana, José E., Meca Lallana, Virginia, Mongay Ochoa, Neus, Moral, E., Oreja Guevara, Celia, Ramió-Torrentà, Lluis, Tellez, Nieves, Romero Pinel, Lucía María, Rodríguez Antiguedad, Alfredo
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/224643
Acceso en línea:https://hdl.handle.net/2445/224643
Access Level:acceso abierto
Palabra clave:Esclerosi múltiple
Neurologia
Neuroimmunologia
Multiple sclerosis
Neurology
Neuroimmunology
Descripción
Sumario:Introduction. On 4 and 5 November 2022, Madrid hosted the 15th edition of the Post-ECTRIMS Meeting, where neurologists specialised in multiple sclerosis outlined the latest developments presented at the 2022 ECTRIMS Congress, held in Amsterdam from 26 to 28 October. Aim. To synthesise the content presented at the 15th edition of the Post-ECTRIMS Meeting, in an article broken down into two parts. Development. This second part describes the new developments in terms of therapeutic strategies for escalation and de-escalation of disease-modifying therapies (DMT), when and in whom to initiate or switch to highly effective DMT, the definition of therapeutic failure, the possibility of treating radiologically isolated syndrome and the future of personalised treatment and precision medicine. It also considers the efficacy and safety of autologous haematopoietic stem cell transplantation, different approaches in clinical trial design and outcome measures to assess DMT in progressive stages, challenges in the diagnosis and treatment of cognitive impairment, and treatment in special situations (pregnancy, comorbidity and the elderly). In addition, results from some of the latest studies with oral cladribine and evobrutinib presented at ECTRIMS 2022 are shown.

Similares en LA Referencia